By Chris Wack
Shares of Telomir Pharmaceuticals climbed up 20% to $5.10 after the company said it saw positive pre-clinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.
The pre-clinical stage pharmaceutical company said the study demonstrated significant reductions in fasting plasma glucose levels to basal levels, improvements in oral glucose homeostasis, and the reversal of insulin resistance to near pre-diabetic levels.
The Miami company said that these effects were also accompanied by increased survival rates in treated subjects, highlighting Telomir-1's ability to potentially address the underlying mechanisms of Type 2 diabetes.
Telomir had its initial public offering in February, with 1 million shares pricing at $7 a share.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 03, 2024 12:04 ET (17:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。